SBIR/STTR Research Award
Development of Conformation Specific Kinase Inhibitors
Award amount
$1,500,000Program and phase
SBIR · Phase IIAward year
2004Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- SUNESIS PHARMACEUTICALS, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- PHS2004-2
- Topic code
- Not reported
Research abstract
DESCRIPTION (provided by applicant): The long-term objective of this proposal is to apply TetheringSM fragment-based drug discovery to obtain novel therapeutics for the treatment of cancer. Conformation-specific inhibitors of the kinase MEK1 provide a n
Technology keywords
Not reported